Life-Sciences-Benelux.com
The Benelux Life Sciences Web Portal

This is a free web portal for the life sciences in Belgium, The Netherlands and Luxembourg... » read more

CROs Cato SMS and Pharm-Olam Announce Merger (2022-01-05)
Newly Combined Company Uniquely Positioned to Serve Small and Mid-Sized Biopharmaceutical Companies News Summary > Research Triangle Park, N.C.-based CATO SMS and Bracknell, U.K.-headquartered Pharm-Olam are merging to create a global biopharmaceutical serv...
Antigon Raises €1.5m to CE Mark Portable Blood Typing Device (2021-12-22)
New corporate investors join Sambrinvest & BeAngels in enlarged round Antigon SA, which is developing ISABO, a portable device for ultimate safety and traceability of blood transfusions via double verification, has raised €1.5m to help it finalize development ...
Thuja Capital Healthcare Fund III – Final Closing at €76m (2021-12-21)
Thuja Capital Management, an early stage life sciences investor, today announces the final close of its Thuja Capital Healthcare Fund III ("Fund III") at EUR 76M. Fund III is focused on investing in early stage companies that develop novel therapeutics, medical dev...
Argenx: FDA Approves Vyvgart in Myasthenia Gravis (gMG) (2021-12-20)
> VYVGART is the first-and-only FDA-approved neonatal Fc receptor blocker > 68% of anti-acetylcholine receptor (AChR) antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis - Activities of Daily Living (MG-ADL) sca...
NorthSea Therapeutics $80m Series C Led by Ysios & Forbion (2021-12-17)
Financing co-led by Ysios Capital and Forbion Growth NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, today announces the cl...
Anaveon to Raise CHF110m Series B Led by Forbion (2021-12-16)
> Leading international syndicate led by Forbion and corner-stoned by founding investor Syncona > Confirms depth of support for Anaveon’s approach to developing engineered cytokines in multiple indications Anaveon, a clinical-stage immuno-oncology company, ...
Argobio & GeneCode to Develop GDNF Mimetics for Parkinson’s (2021-12-16)
> A collaboration to develop a new class of small molecule mimetics for the treatment of Parkinson's disease and other indications. > Argobio will fund the development of this innovative project up to €3 million and incorporate a new specialized biotechnology co...
Synerkine Pharma Raises €3.5m in Extended Series A Financing (2021-12-16)
Synerkine Pharma B.V. announced today that it has added EUR 3.5 million to its Series A funding. The extension was led by Flerie Invest, with support from existing investors Thuja Capital and Utrecht Holdings. Synerkine Pharma is a preclinical stage biotech comp...
Wacker & CordenPharma: Formulating Lipid Nanoparticles (2021-12-14)
WACKER and CordenPharma have signed a development partnership in the field of Lipid Nanoparticle formulation. The two companies announced today that they plan to jointly develop know-how and processes for the manufacturing of Lipid Nanoparticles (LNPs) to be used t...
Galapagos Licenses Inflammation Programme from Ryvu (2021-12-14)
Ryvu Therapeutics S.A. (WSE: RVU) announced today that the pre-agreed criteria in the Option, License and Research Collaboration Agreement, announced between Ryvu and Galapagos on April 16, 2020, have been achieved and Galapagos has exercised its exclusive option f...

Life-Sciences-Benelux.com is your doorway to the Benelux life sciences!

[LSBNL] provides free, up-to-date and structured access to

– News
– Products
– Persons
– Organisations
– Financings
– Collaborations

in the Benelux countries Belgium, The Netherlands and Luxembourg.

Access is unrestricted and free, requiring no log in and no user registration.The high-quality content is not related to the advertising, with topical relevance being the criterion for inclusion. [LSBNL] is 100% Made in Germany!

» Start here with the latest News!

Picture EBD Group BioTech Showcase 2022 For Innovators 650x200

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

» top